CN103191268B - Traditional Chinese medicinal composition for treating lung cancer - Google Patents
Traditional Chinese medicinal composition for treating lung cancer Download PDFInfo
- Publication number
- CN103191268B CN103191268B CN201310155086.0A CN201310155086A CN103191268B CN 103191268 B CN103191268 B CN 103191268B CN 201310155086 A CN201310155086 A CN 201310155086A CN 103191268 B CN103191268 B CN 103191268B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicinal composition for treating lung cancer, and belongs to the technical field of traditional Chinese medicines. Against the problem that current medicaments cannot be used for effectively treating lung cancer, the invention provides the traditional Chinese medicinal composition consisting of pseudo-ginseng, lucid ganoderma, tripterygium wilfordii, ginseng, rhizoma calami, pangolin, common andrographis herb, angelica and liquorice. The traditional Chinese medicinal composition is good in anti-cancer activity in the field of treating lung cancer and other solid tumors, and can be used as a medicament for treating lung cancer.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to the therapeutic combination of pulmonary carcinoma, particularly a kind of Chinese medicine composition and application thereof for the treatment of pulmonary carcinoma.
Background technology
At present, cancer is that current serious affects human health, threatens one of principal disease of human life.Cancer together with contingency, forms world today's All Countries three large causes of death with cardiovascular and cerebrovascular disease.Therefore, World Health Organization (WHO) and hygiene department of national governments all classify capture cancer as a top priority as.The method for the treatment of in the world cancer mainly contains three kinds, and the one, adopt surgical excision, removal lesion tissue, prevents cancerous cell diffusion; The 2nd, adopt chemotherapy or radiotherapy, to kill cancerous cell; The 3rd, use Drug therapy.Adopt the method for excision to increase patient's misery, hinder its vigour, expense is huge.By the method for chemotherapy or radiotherapy, in killing cancerous cell, also injure erythrocyte and leukocyte, patient suffers untold misery.
Nonsmall-cell lung cancer is modal pulmonary carcinoma histological type, accounts for 85% left and right of pulmonary carcinoma.Nonsmall-cell lung cancer comprises again the several types such as squamous cell cancer, adenocarcinoma and large cell carcinoma, and the growth of cancer cells of non-small cell carcinoma is slow, and grade malignancy is relatively lower, and it is more late that diffusion transfer occurs.The treatment of nonsmall-cell lung cancer mainly comprises surgical operation therapy, radiotherapy, chemotherapy, Chinese medicine and the novel method for the treatment of take molecular targeted therapy as representative clinically, but nonsmall-cell lung cancer is poor to the sensitivity of chemotherapy, radiotherapy, finding effective Therapeutic Method is the problem that current Treatment for Non-small Cell Lung is needed solution badly.
The history of TCM on Tumor is of long standing and well established, and as an importance of modern combined therapy of tumour, more and more receives publicity in recent years.People from Chinese traditional herbs, seek single pharmaceutically active ingredient or compound recipe is treated cancer tool challenge.
Summary of the invention
There is no very effective Drug therapy for current pulmonary carcinoma, first object of the present invention is to provide a kind of Chinese medicine composition for the treatment of pulmonary carcinoma, and this Chinese medicine composition has good active anticancer aspect pulmonary carcinoma.Chinese medicine composition of the present invention, is made up of the Chinese crude drug of following weight portion: 10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.Above-mentioned Chinese medicine composition can be prepared as follows and obtain: first, according to components by weight percent meter, get each component of following weight portion: 10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae;
Secondly, add the water of 5-10 times of medical material gross weight, soak 60-90 minute, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1-1.3, and this relative density is the testing result under 60 degrees Celsius, and adding ethanol is 75-95%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.
Sweet, the micro-hardship of Radix Notoginseng meridian distribution of property and flavor, tepor.Return liver, stomach warp.Function cures mainly removing stasis to stop bleeding, promoting blood circulation and detumescence analgesic therapy.Cure mainly various go out blood disorder, tumbling down congestive edema, obstruction of qi in the chest and cardialgia.Modern pharmacology confirms that its main pharmacological has two: (1) antitumor action: arasaponin Rd can make the tumor cell 92% of cultivating be suppressed, and Rd also has obvious inhibitory action to the oncocyte of cultivating.Saponin Rhl can suppress the growth of murine melanoma (B16), make cancerous cell again induction be reversed into non-cancerous cell.Radix Notoginseng decoct has inhibitory action to JYC26 in vivo; Polysaccharide body in Radix Notoginseng can obviously suppress murine sarcoma-180 in vivo; Radix Notoginseng also has antiphagin activity.(2) impact on immunologic function: Radix Notoginseng total arasaponins can improve macrophage phagocytosis of mice and humoral immune function.In Radix Notoginseng, to the influential composition of immunologic function, be mainly Radix Notoginseng total arasaponins and Radix Notoginseng polysaccharide.In addition, pseudo-ginseng water immersion can be shortened rabbit clotting time, and platelet count is increased and has an anastalsis; Rat experiment arthritis is had to obvious preventive and therapeutic action; Nervus centralis is had to excitement, inhibitory action, also have analgesic activity; Can obviously increase coronary artery blood flow, reduce myocardial oxygen consumption; Also have the effects such as antiinflammatory, adrenal cortex reinforcing function.
Ganoderma is China's Chinese medicine material, contains several physiological active substances, has strengthening the body resistance, strengthens the effects such as body immunity, and wherein triterpenoid compound is topmost effective ingredient.Active component triterpenoid compound scalable human body 100 several genes in Ganoderma; When modern medicine uses fingerprint pattern technology to study Ganoderma class medicine, find more than 20 kind of triterpene, wherein 8 kinds is new cancer-resisting substance.Squama Manis is good at walking to alter, and property specially row is loose, energy promoting blood circulation to remove blood stasis, current meridians; Radix Angelicae Sinensis, its property is sweet, pungent, warm, returns liver, the heart, spleen channel, enriching blood and invigorate blood circulation, is the first medicine of Chinese medicine hematonic, containing this lactone of algae, n-butene phthalein lactone, benzene penta phenol phosphorus carboxylic acid, angelicone, fragrant Jing Jie phenol, 2,4-dihydro acid phthalic anhydride etc., separately contain choline and 13 seed amino acids, polysaccharide sucrose, vitamin B12, category-A material and folic acid, nicotinic acid, cupreol etc., in-vitro screening has inhibition tumor cell effect, and suppression ratio is in 50%～70% left and right.
Rhizoma Acori Calami is warm in nature, acrid in the mouth, hardship, GUIXIN, spleen, Liver Channel.Function cures mainly has one's ideas straightened out, reduce phlegm, and stomach invigorating, refreshment.The diseases such as, chronic bronchitis vexed for epilepsy, expectorant febrile convulsion, breast abdominal distention.Modern plants learn confirm containing α-, beta-Asarone, cis-Methylisoeugenol, methyleugenol, Rhizoma Acori Graminei enediol (cal-amendiol), Rhizoma Acori Graminei helicene ketone (acorenone), acolamone (shyobunone), acorone (acorone), the large bull ketone of Rhizoma Acori Graminei (acoragermacrone), acorone (acolamone) isoreactivity composition, use it for the tumors such as treatment gastric cancer, pulmonary carcinoma, have good anticancer function.
Herba Andrographis is acanthaceous plant Herba Andrographis (Andrographis paniculata(Burm.f.) Nees) herb or leaf, main product is in the province such as Guangdong, Fujian, also introduce a fine variety on the ground such as Central China, North China, northwest.There is heat-clearing and toxic substances removing, antiinflammatory, reducing swelling and alleviating pain effect.Cure mainly bacillary dysentery, urinary tract infection, acute tonsillitis, enteritis, pharyngolaryngitis, pneumonia and influenza etc., external can be treated furuncle toxic swelling, trauma infection contamination etc.
Radix Tripterygii Wilfordii is the root of Celastraceae plant Radix Tripterygii Wilfordii, cries again Caulis Fibraureae, beeswax rattan, cabbageworm medicine, red medicine, water Folium illicii Lanceolati, main product in Fujian, the ground such as Zhejiang, Anhui, Henan.Bitter in the mouth, pungent, cool in nature, poison greatly.Return liver, kidney channel.Effect expelling wind and removing dampness, removing obstruction in the collateral to relieve pain, reducing swelling and alleviating pain, removing toxic substances parasite killing.For damp and hot tuberosity, the long-pending poison of carcinoma, treat lepra reaction, rheumatoid arthritis etc. with it clinically, pharmacological research also shows that it has the effect such as antitumor, antiinflammatory.
Radix Notoginseng, Ganoderma and Radix Tripterygii Wilfordii have effect of dispersing swelling and dissipating binds, detoxicating and fighting cancer; Radix Ginseng, Rhizoma Acori Calami, Squama Manis blood circulation promoting and blood stasis dispelling, removing mass dredging collateral; Reuse Radix Angelicae Sinensis and Herba Andrographis, with QI invigorating righting, beneficial blood is enriched blood, and makes eliminating evil just wound, helps just with eliminating evil; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, and play altogether effect of detoxicating and fighting cancer, hard masses softening and resolving, blood circulation promoting and blood stasis dispelling, QI invigorating righting.
The present invention is by investigating Chinese medicine composition antagonism S180 sarcoma cell mice-transplanted tumor of the present invention experiment, find that Chinese medicine composition provided by the invention has the curative effect of obvious inhibition S180 tumor, this shows that Chinese medicine composition antagonism mice S180 tumor of the present invention has obtained unforeseeable curative effect of medication.Especially the Chinese medicine composition best results of the preferred following components by weight percent of the present invention:
10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.Chinese medicine composition of the present invention can be prepared into the treatment of suitable pharmaceutical preparation for tumor patient, is preferably mixture, capsule and tablet.
In addition, the present invention is the effect to inhibition lung cancer Lewis solid tumor aspect by research Chinese medicine composition of the present invention, experimental result discovery, Chinese medicine composition of the present invention, suppressing to have good therapeutic effect aspect lung cancer Lewis solid tumor, can be used as the drug use of anti-pulmonary carcinoma.Based on this, the invention provides a kind of medical usage of above-mentioned Chinese medicine composition, i.e. the purposes of described Chinese medicine composition in preparation treatment cancer drug, wherein said cancer is preferably pulmonary carcinoma.
In a word, the present invention compared with prior art, has good active anticancer, and can be used as cancer therapy drug use; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good application prospect.
The specific embodiment
Further describe the present invention by the specific embodiment below, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the component that effect is identical, within will become apparent to those skilled in the art that they are all deemed to be included in scope of the present invention.
embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 5 times of medical material gross weight, soak 60 minutes, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 75%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, recovery ethanol is concentrated, adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 2 Chinese medicine composition tablet of the present invention
Prescription: 10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 10 times of medical material gross weight, soak 90 minutes, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.3, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 80%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 8 times of medical material gross weight, soak 80 minutes, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 95%(v/v to containing alcohol amount), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
the experiment of test example 1 Chinese medicine composition antagonism of the present invention S180 sarcoma cell mice-transplanted tumor
1, tested medicine and laboratory animal
Kunming mouse 18～25 g, male and female half and half, totally 50.Mouse sarcoma S180 cells, ftorafur, Chinese medicine composition of the present invention (preparation technology is with embodiment 1-3).
, S180 sarcoma cell mice-transplanted tumor model foundation
S180 cell culture in RPMI-1640,37 ℃, 5%CO
2lower cellar culture, on average goes down to posterity once for every 2 days, and during to exponential phase, being prepared into density with normal saline is 3.0 × 10
7/ mL single cell suspension, under aseptic condition in mouse peritoneal (approximately 5 mices, male and female dual-purpose), inoculate latter about 10 days and see the obvious enlargement of mouse peritoneal, now de-neck is put to death mice, put into the beaker that fills 75% ethanol and soak 2～3 min, the mice of sterilizing is put in superclean bench, picks up abdomen middle part skin with tweezers, cut off Dermal exposure abdominal part in hypogastric region with operating scissors, through abdominal muscles extraction ascites, put into aseptic reagent bottle for subsequent use with asepsis injector.
The ascites of above-mentioned extraction is counted with trypan blue, adopted the transplanting liquid normal saline dilution of tumor cell > 95%, adjust cell number to 2 × 10
7～6 × 10
7individual/moL.
One people fixes mice, and another people's left hand has been pinched the right front axillary region skin of mice, and suitable gauffer inserts 1 mL syringe needle subcutaneous, every mouse inoculation 0.4mL cell suspension.
, grouping and administration
After inoculation, weigh next day, selects the close and healthy mice of body weight to be divided at random 4 groups, and 10 every group, male and female half and half, every the record of weighing.After inoculated tumour cell 24 h, gavage administration (administration classification and administration concentration are as shown in table 1).Every 0.3 mL, every day 1 time, continuous 14 d.
the each group of table 1 dosage regimen
4, testing index:
Empty stomach 24 h after last administration, de-neck is put to death mice, weighs, and strips tumor piece and weighs.Calculate the average tumor of tumour inhibiting rate (%)=(the average tumor weight of the average tumor weight-experimental group of negative control group)/negative control group heavy × 100%
,get tumor and carry out pathological examination.
, result
Through pathological section laboratory observation, that excises is organized as tumor tissues, organizes atypia less.Result of the test shows, the first, and Chinese medicine composition 1-3 group of the present invention all has significant curative effect of medication to S180; The second, the tumour inhibiting rate that Chinese medicine composition of the present invention is 1 group is up to 40.4-43.7%, far away higher than 3 groups of 2 groups of Chinese medicine compositions of the present invention and Chinese medicine compositions of the present invention.This shows, the effect of Chinese medicine composition antagonism mice S180 tumor of the present invention is remarkable, 2 groups of best results of Chinese medicine composition especially of the present invention.
the contrast of table 2 administration forebody-afterbody quality and tumour inhibiting rate
test example 2 Chinese medicine composition of the present invention affects Transplantable Murine Lewis lung cancer tumour inhibiting rate
1 research purpose
Study the solid tumor inhibitory action of the mice of Chinese medicine composition of the present invention to the strain of oxter plantation lung cancer Lewis tumor.
test sample and reference substance
2.1 test sample: Chinese medicine composition of the present invention, cold preservation, airtight preservation
2.2 reference substances: the multiple recovery oral liquid (Yicun Pharmaceutical Co., Ltd., Jiangxi) of gold, room temperature, airtight keeping in Dark Place
2.3 test sample: Chinese medicine composition of the present invention (participating in the embodiment of the present invention 1)
3 laboratory animal grouping and recognition methodss
60 of SPF level KM mices, the quality certification number: 8122, half and half, 4 week age of male and female, 22～26 g.
3.1 group technologies: divide into groups according to completely random group technology; Male and female are divided into groups respectively.
3.2 recognition methodss: adopt 3% picric acid staining, between group, labelling is as shown in table 4.
labelling between table 3 mice group
3.3 animal feeding environmental conditions
Conventional environment, 20～25 ℃, temperature difference per day≤3 ℃; Humidity is 40%～70%; Animal illumination: 15～20 lx; Work illumination: more than 150 lx; After front and off-test are carried out in test, room is carried out to thorough cleaning-sterilizing.Cleaning after whole ends of job every day, sterilization.
3.4 feedstuffs, bedding and padding and drinking-water
SPF Mus material, and irradiated feed (lot number: 10063023), conventional raising, free choice feeding, freely drinks water;
4 test methods
4.1 dosage design: administration group dosage designs in table 5.
Postvaccinal mice is divided into 6 groups at random, 10 every group, male and female half and half.
table 4 mice dosage and mode
4.2 test methods:
Mice lung cancer Lewis tumor strain cell culture in RPMI-1640,37 ℃, 5%CO
2lower cellar culture, on average goes down to posterity once for every two days, and during to exponential phase, being prepared into density with normal saline is 3.0 × 10
7individual/ml single cell suspension, at aseptic condition hemostasis in mouse peritoneal, inoculate latter 7 days and see the obvious enlargement of mouse peritoneal, now, de-neck is put to death, and puts into the beaker that fills 75% ethanol and soaks 2～3 minutes, and the mice after sterilization is put into superclean bench, expose abdominal part, put into aseptic reagent bottle by asepsis injector extraction ascites for subsequent use.Above-mentioned ascites is counted with trypan blue, with normal saline dilution, adjusted cell number to 1.0 × 10
7individual/ml, is inoculated in the right oxter of mice, every 0.4ml.
After animal inoculation tumor the 4th day starts administration, presses table 6 gastric infusion every day 1 time (every morning administration); The normal saline of model group gavage equivalent.Successive administration 10 days.
index detects
5.1 body weight
Detect frequency: before grouping and before dissecting, weigh animal body weight on an empty stomach.
Instrument and equipment: ACS-3A-a type electronic scale, Shanghai Dahua Electronic Scale Factory
5.2 tumor quality
Detect frequency: administration finishes test after 10 days, sacrificed by exsanguination, cuts open inspection.
The histoorgan of weigh: oxter tumor
Cut open detecting method: lumbar injection 2% pentobarbital sodium (0.2 mlkg
-1) anesthesia, after abdomen cardinal vein is got blood, cut off ventral aorta sacrificed by exsanguination, then carry out conventional oxter and get tumor.
Instrument and equipment: BS224S type electronic balance, Beijing Sai Duolisi instrument system company limited
ACS-6A type electronic price computing scale, Shanghai Dahua Electronic Scale Factory
6 data statistics processing methods
Test data with
represent, adopt SPSS 11.5 statistical softwares to carry out date processing.
experimental result
Experimental result shows (experimental result is in table 5):
Compared with model group, the tumour inhibiting rate of Chinese medicine composition low dose group of the present invention and high dose group obviously improves, and has significant difference.
Above experimental result further illustrates, and Chinese medicine composition of the present invention, suppressing to have good therapeutic effect aspect lung cancer Lewis solid tumor, can be used as the drug use of anti-pulmonary carcinoma.
The impact of table 5 Chinese medicine composition of the present invention and tumour inhibiting rate heavy on mouse lung carcinoma (
)
Attention:
▲with the comparison of model group group, p<0.05.
Claims (4)
1. treat a Chinese medicine composition for pulmonary carcinoma, it is characterized in that being made by the Chinese medicine material of following weight portion: 10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae.
2. the preparation method for the treatment of as claimed in claim 1 the Chinese medicine composition of pulmonary carcinoma, is characterized in that comprising the steps:
First, get following Chinese crude drug according to weight portion: 10 parts, 15 parts of Radix Notoginseng, 12 parts of Ganodermas, 12 parts of Radix Tripterygii Wilfordiis, 10 parts of Radix Ginsengs, 10 parts of Rhizoma Acori Calami, 10 parts of Squama Maniss, 10 parts of Herba Andrographis, 12 parts of Radix Angelicae Sinensis and Radix Glycyrrhizae;
Secondly, add the water of 5-10 times of medical material gross weight, soak 60-90 minute, decoct 2 times, each 3 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1-1.3, and this relative density is the testing result under 60 degrees Celsius, and adding ethanol is 75-95%v/v to containing alcohol amount, leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.
3. the Chinese medicine composition for the treatment of pulmonary carcinoma as claimed in claim 1, is characterized in that: described Chinese medicine composition is mixture, tablet or capsule.
4. described in claim 1 or 3, treat the Chinese medicine composition of pulmonary carcinoma and treat the purposes in lung-cancer medicament in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310155086.0A CN103191268B (en) | 2013-04-29 | 2013-04-29 | Traditional Chinese medicinal composition for treating lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310155086.0A CN103191268B (en) | 2013-04-29 | 2013-04-29 | Traditional Chinese medicinal composition for treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191268A CN103191268A (en) | 2013-07-10 |
| CN103191268B true CN103191268B (en) | 2014-07-09 |
Family
ID=48714202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310155086.0A Active CN103191268B (en) | 2013-04-29 | 2013-04-29 | Traditional Chinese medicinal composition for treating lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191268B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768399A (en) * | 2014-02-28 | 2014-05-07 | 郭成业 | Traditional Chinese medicinal composition for treating lung cancer and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961466A (en) * | 2010-10-09 | 2011-02-02 | 何龙 | Snake venom capsule for treating cancer |
-
2013
- 2013-04-29 CN CN201310155086.0A patent/CN103191268B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961466A (en) * | 2010-10-09 | 2011-02-02 | 何龙 | Snake venom capsule for treating cancer |
Non-Patent Citations (5)
| Title |
|---|
| 《肺癌的中西医结合治疗》;张家骝等;《云南中医中药杂志》;19951231;第16卷(第5期);第8－10页 * |
| 《论中医药防治恶性肿瘤的优势》;王羲明;《山东中医杂志》;19941231;第13卷(第7期);第308－312页 * |
| 张家骝等.《肺癌的中西医结合治疗》.《云南中医中药杂志》.1995,第16卷(第5期),第8－10页. |
| 王羲明.《论中医药防治恶性肿瘤的优势》.《山东中医杂志》.1994,第13卷(第7期),第308－312页. |
| 纪钧等.《无》.《中医治癌经验精华》.江苏科学技术出版社,1999,第73－74页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191268A (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102845745A (en) | Dendrobium officinale health-care product | |
| WO2013071727A1 (en) | Anti-tumor traditional chinese medical composition | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| KR20190124197A (en) | Chinese herbal composition for the treatment of tumor and its manufacturing method and application | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN108743796B (en) | Traditional Chinese medicine composition for treating lung cancer and application thereof | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN106309758B (en) | Pharmaceutical composition for resisting gastrointestinal cancer | |
| CN104056242A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and preparation method thereof | |
| CN101062374B (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN103768570B (en) | A kind of Chinese medicine composition for the treatment of acute cholecystitis and preparation method thereof | |
| CN101011543A (en) | Antineoplastic medicine composition | |
| CN104367673A (en) | Traditional Chinese medicine composition for treating chicken coccidiosis | |
| CN102716382A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
| CN114159533B (en) | Traditional Chinese medicine composition for treating multiple drug-resistant bacterial infection and application thereof | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN101564409B (en) | Application of traditional Chinese indian lettuce in preparation of diabetes drugs | |
| CN104096065A (en) | Traditional Chinese medicine composition for treating non-small cell lung cancer | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN104116778B (en) | A kind of Chinese medicine composition, its extract and application | |
| CN105641148A (en) | Application of bitter orange volatile oil extract in preparation of antidepressant drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BINZHOU MEDICAL UNIVERSITY HOSPITAL Free format text: FORMER OWNER: CUI XINMING Effective date: 20140610 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gao Lixia Inventor after: Ning Fangling Inventor after: Shang Xiqin Inventor before: Liu Xuejian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU XUEJIAN TO: GAO LIXIA NING FANGLING SHANG XIQIN Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 256600 BINZHOU, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140610 Address after: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Applicant after: Binzhou Medical University Hospital Address before: 266200, No. seven, 179 village, Wenquan Town, Jimo, Shandong, Qingdao Applicant before: Cui Xinming |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CUI XINMING Free format text: FORMER OWNER: BINZHOU MEDICAL UNIVERSITY HOSPITAL Effective date: 20140718 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 256600 BINZHOU, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140718 Address after: 266200 No. seven village, 179 hot springs town, Shandong, Jimo Patentee after: Cui Xinming Address before: 256600 No. two, No. 661, the Yellow River Road, Shandong, Binzhou Patentee before: Binzhou Medical University Hospital |
|
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CUI XINMING Effective date: 20140826 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140826 Address after: 226200 Qidong chemical industry park, Jiangsu, Nantong Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD. Address before: 266200 No. seven village, 179 hot springs town, Shandong, Jimo Patentee before: Cui Xinming |